Antibody Information

General Information of This Antibody
Antibody ID
ANI0MMYXZ
Antibody Name
Anti-NECTIN2 mAb c12G1
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Nectin-2 (NECTIN2)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
C12G1-DM1 [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 9 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 0.00% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian serous cystadenocarcinoma SK-OV-3 cells CVCL_0532
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 0.00% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian serous cystadenocarcinoma SK-OV-3 cells CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 10.40% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian serous cystadenocarcinoma SK-OV-3 cells CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 11.50% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian cancer Ovarian cancer cells Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 19.60% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian cancer Ovarian cancer cells Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 32.90% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 46.40% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian cancer Ovarian cancer cells Homo sapiens
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 84.40% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 88.90% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
References
Ref 1 A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models. Int J Mol Sci. 2022 Oct 15;23(20):12358.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.